Memorandum: List of Bulk Drug Substances That May Not Be Used in Compounding Under Sections 503A and 503B
J.ChoudhuryN
doi: 10.3389/fimmu.2026.1726566 Received 16 October 2025 Revised 27 February 2026 Accepted 09 March 2026 Published 30 March 2026 Volume 17 - 2026 Edited by Christian David Sadik, University of Lbeck, Germany Reviewed by Zhaoqi Zhang, Chinese Academy of Sciences (CAS), China Yihua Fan, Hospital of Chengdu University of Traditional Chinese Medicine, China Updates Copyright 2026 Chen, Cheng, Li and Zhao
While BPC-157 has been explored for its involvement in cellular signaling and tissue-related studies, TB-500, a synthetic fragment derived from thymosin beta-4, has attracted attention for its role in studies involving cell migration, actin regulation, and structural organization
But it also creates a barrier, one that keeps thousands of people from ever starting a peptide protocol in the first place
Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells